In a filing, Nurix Therapeutics Inc revealed its Chief Legal Officer Ring Christine unloaded Company’s shares for reported $0.64 million on Nov 24 ’25. In the deal valued at $17.07 per share,37,600 shares were sold. As a result of this transaction, Ring Christine now holds 50,897 shares worth roughly $0.87 million.
Then, CHRISTINE RING bought 37,600 shares, generating $630,176 in total proceeds.
Before that, van Houte Hans sold 6,284 shares. Nurix Therapeutics Inc shares valued at $78,931 were divested by the Chief Financial Officer at a price of $12.56 per share. As a result of the transaction, van Houte Hans now holds 37,592 shares, worth roughly $0.64 million.
A number of analysts have revised their coverage, including Mizuho’s analysts, who began to cover the stock in late October with a ‘”an Outperform”‘ rating. Leerink Partners began covering NRIX with “Market perform” recommendation on March 17, 2025. BTIG Research started covering the stock on December 10, 2024. It rated NRIX as “a Buy”.
Price Performance Review of NRIX
On Tuesday, Nurix Therapeutics Inc [NASDAQ:NRIX] saw its stock fall -0.87% to $17.0. Over the last five days, the stock has gained 34.07%. Nurix Therapeutics Inc shares have fallen nearly -24.01% since the year began. Nevertheless, the stocks have fallen -9.77% over the past one year. While a 52-week high of $23.00 was reached on 01/27/25, a 52-week low of $8.18 was recorded on 04/10/25.
Levels Of Support And Resistance For NRIX Stock
The 24-hour chart illustrates a support level at 16.57, which if violated will result in even more drops to 16.15. On the upside, there is a resistance level at 17.48. A further resistance level may holdings at 17.97.
How much short interest is there in Nurix Therapeutics Inc?
A steep rise in short interest was recorded in Nurix Therapeutics Inc stocks on 2025-11-14, growing by 0.21 million shares to a total of 14.08 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-15 was 13.87 million shares. There was a rise of 1.48%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 06, 2024 when BMO Capital Markets began covering the stock and recommended ‘”an Outperform”‘ rating along with a $35 price target.
